EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The p38α MAPK–MK2 axis drives chemotherapy-mediated nuclear actin remodeling to promote ovarian cancer progression

Xiaoxia Xing, Zhihao Zhang, Longxia Li, Zhouying Shen, Buri Xi iD, Yixuan Yang iD, Min Diao, Li Ye, Junxiu Chen, Guanglei Zhuang, Xiaoming Zhou iD, Ahmed Ashour Ahmed iD und 3 weitere

Proceedings of the National Academy of Sciences · 17.11.2026 · 123 (46)

DOI: 10.1073/pnas.2615905123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 12.11.2026. Verfasst von Xiaoxia Xing und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Ovarian Cancer, Fudan University and Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Actins, Mitogen-Activated Protein Kinase 14, Protein Serine-Threonine Kinases. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality (STCSM), "Pioneer" and "Leading Goose" R&D Program of Zhejiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nuclear F-actin facilitates DNA damage repair and contributes to cancer chemoresistance. However, the regulatory mechanisms controlling its dynamic polymerization in response to genotoxic stress remain poorly defined. A major barrier in nuclear actin research is the lack of tools for precise, high-throughput analysis. To systematically investigate nuclear F-actin assembly in DNA damage response, we developed a deep learning pipeline, named nFANet, for high-throughput detection and analysis of nuclear F-actin. Here, using ovarian cancer—a malignancy where chemoresistance is a major clinical obstacle—as a model, we showed that platinum-based chemotherapy robustly induces nuclear F-actin assembly. A subsequent kinome screening, in combination with the application of nFANet, identified the kinase p38α MAPK as a critical upstream regulator of platinum-induced nuclear F-actin assembly. Mechanistically, the p38α MAPK–MK2 signaling pathway promotes formin-mediated nuclear F-actin assembly in response to chemotherapy. Importantly, pharmacological inhibition or genetic knockout of the p38α MAPK–MK2 pathway sensitized ovarian cancer cells to platinum-based therapy. Our work uncovers a key mechanism governing nuclear actin remodeling under genotoxic stress and lays the foundation for identifying a patient subgroup likely to benefit from therapeutic targeting of this pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsActinsMitogen-Activated Protein Kinase 14Protein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsFemaleHumansMAP-Kinase-Activated Kinase 2Cell Line, TumorCell NucleusAnimalsAntineoplastic AgentsDrug Resistance, NeoplasmDisease ProgressionDNA DamageSignal Transduction

Stichwörter der Autor:innen

MK2chemotherapydeep learningnuclear F-actinp38α MAPK

Substanzen

MAP-Kinase-Activated Kinase 2ActinsMitogen-Activated Protein Kinase 14Protein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Institute for Ovarian Cancer, Fudan University and Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Institute of Cyber-Systems and Control, College of Control Science and Engineering, Zhejiang University, Hangzhou 310058, China.
  • Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
  • Department of Colorectal Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • HIO Technology (Huzhou) Ltd, Huzhou 313000, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai…

ORCID-Profile: Buri Xi, Yixuan Yang, Xiaoming Zhou, Ahmed Ashour Ahmed, Rongyu Zang, Yiyan Zheng

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality (STCSM)
  • "Pioneer" and "Leading Goose" R&D Program of Zhejiang
  • “Pioneer” and “Leading Goose” R&D Program of Zhejiang

Zitieren

APA

Xing, X., Zhang, Z., Li, L., Shen, Z., Xi, B., Yang, Y., Diao, M., Ye, L., Chen, J., Zhuang, G., Zhou, X., Ahmed, A. A., Gong, H., Zang, R., & Zheng, Y. (2026). The p38α MAPK–MK2 axis drives chemotherapy-mediated nuclear actin remodeling to promote ovarian cancer progression. Proceedings of the National Academy of Sciences, 123(46). https://doi.org/10.1073/pnas.2615905123

Vancouver

Xing X, Zhang Z, Li L, Shen Z, Xi B, Yang Y, et al. The p38α MAPK–MK2 axis drives chemotherapy-mediated nuclear actin remodeling to promote ovarian cancer progression. Proceedings of the National Academy of Sciences. 2026;123(46). doi:10.1073/pnas.2615905123

BibTeX
@article{Xing2026,
  author = {Xing, Xiaoxia and Zhang, Zhihao and Li, Longxia and Shen, Zhouying and Xi, Buri and Yang, Yixuan and Diao, Min and Ye, Li and Chen, Junxiu and Zhuang, Guanglei and Zhou, Xiaoming and Ahmed, Ahmed Ashour and Gong, Hai and Zang, Rongyu and Zheng, Yiyan},
  title = {The p38α MAPK–MK2 axis drives chemotherapy-mediated nuclear actin remodeling to promote ovarian cancer progression},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {46},
  doi = {10.1073/pnas.2615905123}
}
Kostenlos starten →